CellTrans, Inc.’s donislecel has a favorable benefit-risk profile for some type 1 diabetics, but the US Food and Drug Administration needs to carefully and narrowly define the small group of patients that should be eligible for the therapy, members of the Cellular, Tissue and Gene Therapies Advisory Committee said on 15 April.
The majority of panel members said the benefits of independence from insulin seen in the majority of patients across CellTrans’...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?